The Biohaven Ltd. (NYSE: BHVN) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, shelf registration materials and other documents filed with the Securities and Exchange Commission. These filings offer detailed insight into Biohaven’s status as a global clinical-stage biopharmaceutical company focused on immunology, obesity, neuroscience and oncology.
Through its Form 8-K reports, Biohaven discloses material events such as underwritten public offerings of common shares, block share transactions under its at-the-market offering program, and updates on its New Drug Application for VYGLXIA (troriluzole) in spinocerebellar ataxia. Earnings-related 8-Ks furnish press releases summarizing quarterly financial results, R&D spending, and portfolio reprioritization decisions that concentrate resources on late-stage programs like opakalim, BHV-1300, BHV-1400 and taldefgrobep alfa.
Other filings reference the company’s effective Form S-3 shelf registration statement, prospectus supplements for equity offerings, and legal opinions related to share issuances. These documents outline the terms of capital raises used to fund Biohaven’s clinical pipeline, including its Kv7 ion channel modulators, MoDE and TRAP extracellular degraders, myostatin-activin pathway inhibitors, antibody-drug conjugates and TYK2/JAK1 inhibitor.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of each filing in clear language. Users can quickly understand the implications of financing transactions, regulatory updates, and clinical program disclosures without reading every technical detail. For deeper research, investors can review full-text filings to track trends in Biohaven’s operating expenses, trial progress and regulatory strategy over time.
Biohaven Ltd. entered into Amendment No. 2 to its Equity Distribution Agreement with J.P. Morgan Securities LLC, establishing an “at-the-market” equity offering program. From May 4, 2026, the company may sell up to an aggregate offering price of $350.0 million in common shares through J.P. Morgan as manager.
Shares may be sold on the New York Stock Exchange or via other negotiated transactions at prevailing market prices, with actual sales determined over time by the company’s capital needs and market conditions. The program is issued under an effective shelf registration statement and related base prospectus and prospectus supplement filed on May 4, 2026.
Biohaven Ltd. is offering common shares having an aggregate offering price of up to $350,000,000 through an amendment dated May 4, 2026 to its equity distribution agreement with J.P. Morgan Securities LLC. The shares will be sold as at-the-market offerings from time to time. The company reported 150,506,490 common shares outstanding as of March 31, 2026. Sales may occur in ordinary brokers’ transactions, to or through market makers, on the NYSE or other permitted venues, and the sales agent may act as agent or principal. The sales agent may receive up to 3.00% of gross proceeds as compensation.
Biohaven Ltd. filed a Form S-3 shelf registration to permit the offering from time to time of common shares, preferred shares, depositary shares, debt securities, warrants, rights, purchase contracts and units, including resale by certain selling shareholders. The shelf contemplates primary issuances and resales by selling stockholders and states proceeds to the company will be used for general corporate purposes. The prospectus incorporates Biohaven’s Form 10-K for the year ended December 31, 2025, its Form 10-Q for the quarter ended March 31, 2026, and Current Reports on Form 8-K (including filings on January 7, 2026 and May 4, 2026), and notes that supplements will specify offering terms, plan of distribution and any selling stockholder details.
Biohaven Ltd. reported a first-quarter 2026 net loss of $130.5M, an improvement from $221.7M a year earlier, driven by sharply lower research and development and general and administrative spending. Total operating expenses fell to $130.4M from $221.6M, reflecting portfolio and cost-optimization efforts.
Cash and cash equivalents were $273.1M and marketable securities were $74.7M as of March 31, 2026, supporting management’s view that existing liquidity should fund operations for at least one year after the statements’ issuance. Net cash used in operating activities was $149.9M for the quarter.
To bolster its balance sheet, Biohaven issued 17,164,940 common shares under its at-the-market equity program, generating net proceeds of $178.9M and increasing outstanding shares to 150,506,490. Notes payable tied to a revenue-sharing Note Purchase Agreement had a fair value of $241.9M, highlighting a significant non-traditional financing obligation linked to future sales and regulatory milestones. The company continues to focus on three key late-stage programs in Kv7 ion channel modulation, MoDE/TRAP extracellular protein degraders, and myostatin-activin pathway targeting for neuromuscular and metabolic diseases.
Biohaven Ltd. reported first quarter 2026 results showing a smaller loss and stronger balance sheet while advancing multiple late-stage drug programs. Net loss narrowed to $130.5 million, or $0.88 per share, compared with $221.7 million, or $2.17 per share, a year earlier.
R&D expenses fell to $103.8 million from $187.6 million, mainly from program reprioritization and lower preclinical and share-based compensation costs. Cash, cash equivalents, marketable securities and restricted cash totaled $351.8 million as of March 31, 2026, supporting a broad pipeline across epilepsy, obesity, immunology, oncology and Parkinson’s disease.
The company expects pivotal epilepsy data for opakalim and Phase 2 obesity data for taldefgrobep alfa in the second half of 2026, and plans to start pivotal trials for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy by mid-2026. Non-GAAP adjusted net loss improved to $102.2 million, or $0.69 per share, as Biohaven continues disciplined cost management while progressing its clinical programs.
Biohaven Ltd. reported the results of its 2026 annual meeting of shareholders. Shareholders elected Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin as directors for terms expiring at the 2029 annual meeting, each receiving over 76 million votes in favor and more than 14 million votes against, with additional abstentions and 32,137,064 broker non-votes.
Shareholders also approved the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, with 123,723,636 votes for, 214,123 against, and 1,410,634 abstentions. In addition, they approved the non-binding advisory vote on compensation for the company’s named executive officers, with 87,521,620 votes for, 4,202,883 against, 1,486,826 abstentions, and 32,137,064 broker non-votes.
Biohaven Ltd. director Kishan Mehta received a grant of 68,693 stock options on April 28, 2026. Each option gives the right to buy one common share at an exercise price of $9.61 and expires on April 28, 2036.
According to the vesting terms, all 68,693 options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided Mehta continues to serve with the company through that vesting date.
Biohaven Ltd. director Gregory Bailey reported receiving a grant of stock options as part of his compensation. The award covers 68,693 stock options, each allowing him to buy one common share at an exercise price of $9.61 per share.
The options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company until that vesting date. After this grant, he holds 68,693 options directly, and this filing does not show any open-market buying or selling of shares.
Biohaven Ltd. director Michael Thomas Heffernan received a grant of stock options on April 28, 2026. The award covers 68,693 options, each allowing him to buy one common share at an exercise price of $9.61. After this grant, he holds 68,693 options directly.
These options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company through that date. The options expire on April 28, 2036. This is a compensation-related grant rather than an open-market share purchase or sale.
Biohaven Ltd. director Irina Antonijevic received a grant of stock options covering 68,693 common shares, with an exercise price of 9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to her continuous service, and expire on April 28, 2036.